| Nov 13 |
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
|
| Nov 13 |
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
|
| Nov 11 |
Regeneron Announces Investor Conference Presentations
|
| Nov 10 |
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease
|
| Nov 7 |
Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer
|
| Nov 7 |
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
|
| Nov 6 |
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
|
| Nov 6 |
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
|
| Nov 5 |
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
|
| Nov 5 |
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
|
